| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Amarin Corporation plc$16.03
+0.26 (+1.65%)
C 49Pipeline Score Fair Value Pharma · Commercial
Market Cap
303.58 M
EPS
-1.62
P/E Ratio
-8.93 $
Value Trade
732.59 K
SEC Financials
Q1 2026Dilution Risk
Revenue
45.13 M
R&D Expenses
4.67 M
Operating CF
6.39 M
Total Assets
645.76 M
Total Liabilities
196.35 M
Equity
449.41 M
D/E Ratio
12,345
-1.64 %
Week
-0.35 %
1 Month
-7.26 %
3 Month
-12.28 %
6 Month
-84.32 %
5 Year
-99.88 %
All Time
Cash Data
Cash Position
307.82 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 29, 2026
Overview
Volume
87.09 K
52 Week Range
11.65 - 20.90
% held by Insiders
0.41 %
% held by Institutions
22.19 %
Enterprise Value
1.14 M
Total Shares
20.98 M
Short %
2.99 %
Float Shares
20.89 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C49
Pipeline Score $452M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored1.5x
rNPV / MCap Top 77%
Micro Cap (rank 209 of 905)
Percentile RankAmarin Corporation plc carries a moderate pipeline score (49/100), with $2.3B risk-adjusted pipeline value, led by AMR101 - /day in Hypertriglyceridemia (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMR101 - /day Small molecule | Hypertriglyceridemia | Phase 3 | NCT01047501 | 50% | $1.3B | COMPLETED | 931 | - | - | Feb 1, 2011 | - | Apr 25, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
icosapent ethyl | cardiovascular disease,hypertriglyceridemia | Phase 3 | 2025-08-25 | |||
icosapent ethyl | cardiovascular disease,hypertriglyceridemia | Phase 3 | 2025-08-25 | |||
icosapent ethyl | cardiovascular disease,hypertriglyceridemia | Phase 3 | 2025-08-25 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AMRN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Amarin Corporation plc (AMRN) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
AMRN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AMRN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AMRN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AMRN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
AMRN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AMRNNew REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
Amarin Corporation presented new findings from a post hoc analysis of the REDUCE-IT trial at the EAS Congress 2026. The analysis indicates that risk-weighted apolipoprotein B (RW-apoB) can more effectively identify residual cardiovascular risk in statin-treated patients with elevated triglycerides compared to traditional lipid markers. This suggests RW-apoB's potential for improving risk stratification in clinical practice.
Read more →AMRNAmarin Reports 2026 First Quarter Financial Results
Amarin Corporation reported a 7% increase in total revenue for Q1 2026, driven by higher international sales and positive cash flow for the second consecutive quarter. The company noted strong demand for its product VAZKEPA in Europe, supported by new industry guidelines endorsing Icosapent Ethyl for cardiovascular risk management. Despite a slight decline in European revenue, the overall performance reflects a positive trend under its new business model.
Read more →AMRNAmarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
Amarin Corporation announced it will report its first quarter 2026 financial results on April 29, 2026. A press release will precede a conference call with senior management at 8:00 a.m. ET. The call will be accessible via telephone and online, with a replay available for later access.
Read more →AMRNAmerican College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction
Amarin Corporation highlighted key findings from the ACC Scientific Sessions 2026, emphasizing the role of icosapent ethyl (IPE) in managing elevated triglycerides and cardiovascular risk. The new ACC/AHA guidelines stress the need for complementary therapies beyond statins to address residual cardiovascular risk. Presentations at the event reinforced the efficacy of IPE in high-risk populations, while also noting limitations of current therapies.
Read more →AMRNNew REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
Amarin Corporation announced that new data from the REDUCE-IT study will be presented at the American College of Cardiology's Annual Scientific Session & Expo. The presentations will include a secondary analysis of the efficacy of icosapent ethyl in patients at extreme cardiovascular risk and mechanistic data on lipoprotein(a) oxidation. This highlights Amarin's commitment to addressing cardiovascular disease.
Read more →AMRNEffects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
A recent post hoc analysis of the REDUCE-IT study published in the European Journal of Preventive Cardiology indicates that icosapent ethyl (IPE) significantly reduces total hospitalizations and days lost due to hospitalization and death among patients with cardiovascular disease or diabetes. The analysis involved 8,179 participants over five years, demonstrating the treatment's impact on patient-centered outcomes. Experts emphasize the importance of these findings for improving patients' quality of life.
Read more →AMRNAmarin Reports Fourth Quarter and Full Year 2025 Financial Results
Amarin Corporation reported its fourth quarter and full year 2025 financial results, highlighting a positive shift in operational efficiency and market positioning. The company maintained its U.S. market leadership for VASCEPA and established a long-term partnership for VAZKEPA in Europe. Despite a 21% decrease in total net revenue, significant cost savings and a return to positive cash flow were achieved.
Read more →AMRNThis American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
Amarin Corporation emphasizes the urgent need to utilize existing, proven therapies to combat cardiovascular disease during American Heart Month. Despite advancements, many patients remain untreated or undertreated, contributing to high rates of cardiovascular events. The company calls for a recommitment to data-driven care to address these gaps and save lives now.
Read more →AMRNAmarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
Amarin Corporation plc has announced it will report its fourth quarter and full year 2025 financial results on February 25, 2026. The company will issue a press release in the pre-market hours, followed by a conference call at 8:00 a.m. ET. Investors can participate via telephone or online, with replay options available afterward.
Read more →AMRNAmarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
Amarin Corporation highlights advancements in therapies for patients with elevated triglycerides, particularly emphasizing the role of its VASCEPA/VAZKEPA products. These therapies are expected to enhance patient access and treatment strategies, especially through payor-driven step therapy programs. VASCEPA has shown significant efficacy in reducing cardiovascular events and is approved in multiple countries.
Read more →AMRNNew REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
Amarin Corporation presented a new post hoc analysis from the REDUCE-IT study at the AHA Scientific Sessions 2025, demonstrating that icosapent ethyl significantly reduces cardiovascular events in high-risk patients, regardless of aspirin use. This reinforces the drug's role in managing cardiovascular risk alongside statin therapy. The analysis follows an FDA update on fibrates, emphasizing the need for effective treatment options.
Read more →AMRNAmarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
Amarin Corporation announced it will present new analyses at the AHA Scientific Sessions 2025, showcasing the efficacy of VASCEPA in reducing cardiovascular risk. The data will include findings from the REDUCE-IT study and mechanistic studies on Eicosapentaenoic Acid (EPA). This presentation aims to further establish VASCEPA's role in cardiovascular care.
Read more →AMRNAmarin Reports Third Quarter 2025 Financial Results
Amarin Corporation reported its Q3 2025 financial results, showcasing a successful transition to a fully partnered commercialization model across international markets. The company experienced a 17% increase in total net revenue compared to Q3 2024, driven by higher U.S. sales. Operating expenses decreased significantly, reflecting the benefits of a global reorganization. Amarin aims for sustainable positive free cash flow by 2026.
Read more →AMRNAmarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
Amarin Corporation has expressed strong support for the FDA's recent decision to revise the labeling for fenofibrate drugs, emphasizing the lack of cardiovascular benefits associated with these medications. The updated labeling aims to encourage healthcare providers to prioritize clinically proven therapies for cardiovascular risk reduction. Amarin advocates for the use of its product, VASCEPA, as a more effective alternative for patients at risk of cardiovascular events.
Read more →AMRNAmarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
Amarin Corporation plc has announced it will report its third quarter 2025 financial results on October 29, 2025. The company will issue a press release before the market opens and host a conference call with senior management at 8:00 a.m. ET. Participation details for the call and replay options have been provided.
Read more →AMRNAmarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
Amarin Corporation, in partnership with HLS Therapeutics, will present new scientific data at the Canadian Cardiovascular Congress (CCC) from October 23-26, 2025. The presentations will focus on the clinical benefits of Icosapent Ethyl (IPE) and the mechanistic effects of Eicosapentaenoic Acid (EPA) on cardiovascular health. This collaboration underscores their commitment to advancing cardiovascular care.
Read more →AMRNAmarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
Amarin Corporation presented new in vitro data at the ESC Congress 2025, showcasing the effects of eicosapentaenoic acid (EPA) on lipoprotein(a) oxidation and its anti-inflammatory mechanisms. The findings suggest that EPA may reduce cardiovascular risk beyond triglyceride lowering, particularly in patients with elevated Lp(a). This research advances the understanding of EPA's role in managing atherosclerotic cardiovascular disease.
Read more →AMRNNew REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
Amarin Corporation presented new analyses from the REDUCE-IT trial at the ESC Congress 2025, highlighting the benefits of VASCEPA/VAZKEPA (icosapent ethyl) in reducing cardiovascular disease risk in high-risk patient subgroups. The findings indicate significant reductions in total hospitalizations and cardiovascular events, reinforcing the therapy's role in managing complex conditions like cardiovascular-kidney-metabolic syndrome. The ESC/EAS Dyslipidemias Guideline reaffirmed high-dose icosapent ethyl as a recommended treatment for patients with elevated triglyceride levels.
Read more →AMRNNew Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
Amarin Corporation announced that new analyses from the REDUCE-IT trial and mechanistic studies of icosapent ethyl (IPE) will be presented at the ESC Congress 2025. These presentations aim to highlight IPE's multifaceted cardioprotective effects, including its role in reducing cardiovascular risk and hospitalization duration. The findings are expected to deepen the understanding of IPE's mechanisms in cardiovascular care.
Read more →Competitive Position
How AMRN ranks across every disease it competes inCompetitive Position is a premium feature
See how AMRN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial